Photocure appoints Jane Healy as Vice President and General Manager EMEA

26 Mar 2025 08:00 CET

Press Release - Oslo, Norway, March 26, 2025: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, today announced the appointment of Jane Healy as Vice
President and General Manager EMEA.

Ms. Healy joined Photocure in March 2025 to lead the European Organization. Her
extensive international experience in the medical device field covers sales,
marketing, general management and functional leadership. Over the past 30 years
she has worked for three major medical device organizations; St Jude Medical, CR
Bard and over 20 years for Boston Scientific.

In her most recent role, Jane Healy was VP EMEA for the Peripheral Interventions
Division for Boston Scientific, responsible for driving the growth strategy for
the region. She brings a blend of strong commercial acumen, results orientation
and a passion for enabling and driving results through her teams. Jane Healy
holds a BA (Hons) in Modern Languages from Cambridge University and she speaks
English, French, German and Italian.

"I am pleased to welcome Jane to the Photocure team at such an important time
for us. Her background and extensive experience in healthcare and medical
devices will be instrumental in achieving our growth ambitions in uro-oncology.
Her track record of building successful international teams make her the ideal
fit to lead Photocure's European Organization, at a time when the Uro-Oncology
world is experiencing tremendous innovation and attention in healthcare. Jane
will report directly to me in her role as GM EMEA and will be a member of
Photocure's executive leadership team. says Dan Schneider, President and Chief
Executive Officer of Photocure.

Photocure's European Organization was launched following the agreement to regain
the Hexvix[®] sales, marketing and distribution rights in Europe and other
markets from Ipsen Pharma SAS on 1 October 2020. The European team has gained
momentum since re-introducing BLC to the European market.

"I am pleased with the ongoing developments in Europe and look forward to Jane's
leadership as we continue pursuing our ambition to lead the change that will
improve the lives of bladder cancer patients. We know the importance of using
Blue Light Cystoscopy in the precision diagnostic pathway for bladder cancer,
where accurate staging and resection helps determine the optimal treatment
decisions", Schneider concludes.

Note to editors:

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.
This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 949 000 prevalent cases (5-year prevalence rate)[1a],
614 000 new cases and more than 220 000 deaths in 2022.[1b]
Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]
Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]

[1 ]Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [February 2024].
[2 ]Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3 ]Sievert KD et al. World J Urol 2009;27:295-300
[4 ]Bladder Cancer. American Cancer Society.
https://www.cancer.org/cancer/bladder-cancer.html

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)
Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all
other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S.
and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to https://photocure.com/partners/our-partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com/news

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

More information:
Access the news on Oslo Bors NewsWeb site

642229_Release.pdf